Public Health

The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

The first orally disintegrating birth control tablet was designed for individuals who have trouble swallowing their medication.

The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.